PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thomas Hamilton to Speak About the Cytokine Regulation at Cytokines Conference on January 29-31, 2014 in San Diego, California - Thomas Hamilton will present about “Regulation of TLR-Induced Cytokine Expression by Environmental Stress” at the 12th Cytokines & Inflammation Conference, to be held January 29-31, 2014 in San Diego, CA
Thomas Hamilton to Speak About the Cytokine Regulation at Cytokines Conference on January 29-31, 2014 in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/10/07 - Thomas Hamilton will present about “Regulation of TLR-Induced Cytokine Expression by Environmental Stress” at the 12th Cytokines & Inflammation Conference, to be held January 29-31, 2014 in San Diego, CA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Hamilton currently serves as the Chairman of the Department of Immunology at the Lerner Research Institute of the Cleveland Clinic Foundation, where his research focuses on studying the regulation of inflammatory cytokine and chemokine gene expression. His laboratory has made substantial contributions to the understanding of both transcriptional and post-transcriptional control mechanisms regulating innate inflammatory responses in myeloid and non-myeloid cell populations.

He will discuss how cellular stress can amplify the expression of selected inflammatory cytokines in myeloid cell populations. For example, TLR-stimulated CXCL1 and CXCL2 chemokine mRNA levels are enhanced more than ten-fold in stressed macrophages, while mRNAs encoding CCL5 and CXCL10 are not. Other pro-inflammatory cytokines that show elevated levels of stress include TNFa, IL-1a, and IL-6.

Stress responses also enhance chemokine protein levels during peritoneal inflammation. TLR4 is the most sensitive, though other TLR responses are also enhanced. Stress-enhanced chemokine gene expression is mediated by altered transcription, but NFkB activation, though necessary, does not appear to be the target of stress.

Similarly, while the IRF3 transcription factor is linked to TLR4 signaling, IRF3 is not required for stress sensitivity. Though mediators of endoplasmic reticulum stress (IRE-1, XBP-1, and CHOP) have been implicated in altered inflammatory cytokine responses, they are not required for amplification of TLR4-induced chemokine expression. Rather, RIP1, a kinase that participates in TLR3 andTLR4/TRIF signaling, is required through a pathway that involves stress-dependent increases in RIP1 protein levels and activation via ubiquitinylation.

Dr. Hamilton will discuss how these findings, which identify novel mechanisms for modulating the magnitude and duration of selective TLR-induced chemokine and cytokine gene expression, further establish the importance of environmental stress in coordinating the outcomes of cellular and tissue injury.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thomas Hamilton to Speak About the Cytokine Regulation at Cytokines Conference on January 29-31, 2014 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)